Marijke Kamsteeg

Marijke Kamsteeg

Auto-generated profile, based on publicly available information

Marijke Kamsteeg

Department of Dermatology, Radboud University Medical Center, Radboud University, The Netherlands

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2003 in Oncogene
Verified
Journal Article
Closed access
MKMarijke Kamsteeg
Marijke Kamsteeg
TRthomas Rutherford
thomas Rutherford
Eva SapiEva Sapi
Eva Sapi
BHBozena Hanczaruk
Bozena Hanczaruk
SSShoreh Shahabi
Shoreh Shahabi
Gil MorGil Mor
Gil Mor

1 February 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JSJos Smits
Jos Smits
TEThomas H.A. Ederveen
Thomas H.A. Ederveen
GRGijs Rikken
Gijs Rikken
NBNoa J.M. van Den Brink
Noa J.M. van Den Brink
IVIvonne M.J.J. van Vlijmen-Willems
Ivonne M.J.J. van Vlijmen-Willems
EBEllen H. van den Bogaard
Ellen H. van den Bogaard

16 February 2023 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
PDF file
CBCeleste M. Boesjes
Celeste M. Boesjes
LGLiana F. Van der Gang
Liana F. Van der Gang
NZNicolaas P.A. Zuithoff
Nicolaas P.A. Zuithoff
DBDaphne S. Bakker
Daphne S. Bakker
LSLotte S. Spekhorst
Lotte S. Spekhorst
MBMarjolein S. De Bruin-Weller
Marjolein S. De Bruin-Weller
Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the effectiveness of 16 weeks of upadacitinib treatment for moderate-to-severe atopic dermatitis in adult patients, including those with previous inadequate response to dupilumab and/or baricitinib, in daily practice. A total of 47 patients from the Dutch BioDay registry treated with upadacitinib were included. Patients were evaluated at baseline, and after 4, 8 and 16 weeks of treatment. Effectiveness was assessed by clinician- and patient-reported outcome measurements. Safety was assessed by adverse events and laboratory assessments. Overall, the probabilities (95% confidence intervals) of achieving Eczema Area and Severity Index ≤ 7 and Numerical Rating Scale – pruritus ≤ 4 were 73.0% (53.7–86.3) and 69.4% (48.7–84.4), respectively. The effectiveness of upadacitinib was comparable in patients with inadequate response to dupilumab and/or baricitinib and in patients who were naïve for these treatments or who had stopped such treatments due to adverse events. Fourteen (29.8%) patients discontinued upadacitinib due to ineffectiveness, adverse events or both (8.5%, 14.9% and 6.4%, respectively). Most frequently reported adverse events were acneiform eruptions (n = 10, 21.3%), herpes simplex (n = 6, 12.8%), nausea and airway infections (both n = 4, 8.5%). In conclusion, upadacitinib is an effective treatment for patients with moderate-to-severe atopic dermatitis, including those with previous inadequate response to dupilumab and/or baricitinib treatment.

5 December 2022 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
EKEsmé Kamphuis
Esmé Kamphuis
CBCeleste M. Boesjes
Celeste M. Boesjes
LLLaura Loman
Laura Loman
DBDaphne S. Bakker
Daphne S. Bakker
MPMila Poelhekken
Mila Poelhekken
MSMarie L.A. Schuttelaar
Marie L.A. Schuttelaar
Background: Dupilumab has proven to be an effective and safe treatment for atopic dermatitis (AD) in pediatric patients in clinical trials. However, few daily practice studies are available. The aim of this study is to evaluate the effect of 28 weeks dupilumab treatment on effectiveness, safety, and serum biomarkers in pediatric patients with moderate‐to‐severe AD in daily practice.Methods: Patients visited the outpatient clinic at baseline, 4, 16, and 28 weeks of treatment. Disease severity was assessed by the Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), Numeric Rating Scale (NRS)‐pruritus and ‐pain, and the Patient‐Oriented Eczema Measure (POEM). Side effects were evaluated. Nineteen severity‐associated serum biomarkers were measured. Predicted‐EASI (p‐EASI) was calculated.Results: Sixty‐one patients were included. Respectively 75.4%, 49.2%, and 24.6% reached EASI‐50, EASI‐75, and EASI‐90 and 36.1% achieved an IGA‐score (almost) clear. Improvement of ≥4 points on POEM, NRS‐pruritus, and NRS‐pain was reached by 84.7%, 45.3%, and 77.4%, respectively. Most reported side effects were conjunctivitis (n = 10) and headache (n = 4). Biomarkers TARC, PARC, periostin, sIL‐2Ra, and eotaxin‐3 significantly decreased during treatment. The p‐EASI showed a significant correlation with disease severity.Conclusion: Dupilumab treatment significantly improved disease severity and disease‐associated symptoms and decreased severity‐associated serum biomarkers in pediatric AD patients in daily practice.

24 November 2022 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
PDF file
CBCeleste M. Boesjes
Celeste M. Boesjes
EKEsmé Kamphuis
Esmé Kamphuis
NZNicolaas P.A. Zuithoff
Nicolaas P.A. Zuithoff
DBDaphne S. Bakker
Daphne S. Bakker
LLLaura Loman
Laura Loman
MBMarjolein S. De Bruin-Weller
Marjolein S. De Bruin-Weller
Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of moderate-to-severe atopic dermatitis. However, daily practice data are limited. Therefore, this multicentre prospective study evaluated the effectiveness and safety of 16-weeks’ treatment with baricitinib in adult patients with moderate-to-severe atopic dermatitis in daily practice. A total of 51 patients from the BioDay registry treated with baricitinib were included and evaluated at baseline and after 4, 8 and 16 weeks of treatment. Effectiveness was assessed using clinician- and patient-reported outcome measurements. Adverse events and laboratory assessments were evaluated at every visit. At week 16, the probability (95% confidence interval) of achieving Eczema Area and Severity Index ≤ 7 and numerical rating scale pruritus ≤ 4 was 29.4% (13.1–53.5) and 20.5% (8.8–40.9), respectively. No significant difference in effectiveness was found between dupilumab non-responders and responders. Twenty-two (43.2%) patients discontinued baricitinib treatment due to ineffectiveness, adverse events or both (31.4%, 9.8% and 2.0%, respectively). Most frequently reported adverse events were nausea (n = 6, 11.8%), urinary tract infection (n = 5, 9.8%) and herpes simplex infection (n = 4, 7.8%). In conclusion, baricitinib can be an effective treatment option for moderate-to-severe atopic dermatitis, including patients with non-responsiveness on dupilumab. However, effectiveness of baricitinib is heterogeneous, which is reflected by the high discontinuation rate in this difficult-to-treat cohort.

30 July 2025 in Journal of Dermatological Treatment
Verified
Journal Article
Open access
FVFlorence Vroman
Florence Vroman
LRLisa P. van der Rijst
Lisa P. van der Rijst
OBOctavian I. Bacoş-Cosma
Octavian I. Bacoş-Cosma
NZNicolaas P. A. Zuithoff
Nicolaas P. A. Zuithoff
MKMarijke Kamsteeg
Marijke Kamsteeg
MGMarlies de Graaf
Marlies de Graaf
Upadacitinib is approved for treating moderate-to-severe atopic dermatitis (AD) aged ≥12 years. We evaluated upadacitinib's effectiveness and safety in AD adolescents in daily practice. Fifteen adolescent AD patients from the BioDay registry, treated with upadacitinib 15 mg once daily were evaluated at baseline and after 4, 8, 16, and 28 weeks. Effectiveness was assessed using Eczema Area and Severity Index (EASI) score and Investigator Global Assessment (IGA) score. Patient-reported outcomes included Numeric Rating Scale (NRS) for pruritus and presence of sleep disturbance. Adverse events (AEs) were evaluated at each visit. Mean EASI score significantly decreased from 13.4 (95% CI 8.5-18.3) to 7.8 (95% CI 2.4-13.3) after 28 weeks (p = .002). Mean NRS pruritus significantly decreased from 6.5 (95% CI 4.9-8.2) to 4.8 (95% CI 3.0-6.6) after 28 weeks (p = .003). At week 16, 75.0% (95% CI 46.8-91.1) achieved EASI ≤7, and 50.0% (95% CI 25.4-74.6) achieved NRS pruritus ≤4. Overall, 31 AEs were reported in 10 patients (66.7%). Five patients (33.3%) discontinued treatment: two due to ineffectiveness, two due to AEs, and one due to laboratory monitoring problems. Our findings indicate that upadacitinib is effective and relatively safe for adolescents with moderate-to-severe AD; however, 33.3% discontinued treatment.